R
Richard M. Weinshilboum
Researcher at Mayo Clinic
Publications - 26
Citations - 1216
Richard M. Weinshilboum is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacogenomics & Major depressive disorder. The author has an hindex of 14, co-authored 26 publications receiving 1001 citations. Previous affiliations of Richard M. Weinshilboum include University of Rochester.
Papers
More filters
Journal ArticleDOI
Implementing genomic medicine in the clinic: the future is here
Teri A. Manolio,Rex L. Chisholm,Brad Ozenberger,Dan M. Roden,Marc S. Williams,Richard Trevor Wilson,David P. Bick,Erwin P. Bottinger,Murray H. Brilliant,Charis Eng,Kelly A. Frazer,Bruce R. Korf,David H. Ledbetter,James R. Lupski,Clay B. Marsh,David A. Mrazek,Michael F. Murray,Peter H. O'Donnell,Daniel J. Rader,Mary V. Relling,Alan R. Shuldiner,David Valle,Richard M. Weinshilboum,Eric D. Green,Geoffrey S. Ginsburg +24 more
TL;DR: The National Human Genome Research Institute brought together a number of institutions to describe their ongoing projects and challenges, identify common infrastructure and research needs, and outline an implementation framework for investigating and introducing similar programs elsewhere.
Journal ArticleDOI
“The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems”
Jasmine A. Luzum,Jasmine A. Luzum,Ruth E. Pakyz,Amanda R. Elsey,Cyrine E. Haidar,Josh F. Peterson,Michelle Whirl-Carrillo,Samuel K. Handelman,Kathleen Palmer,Jill M. Pulley,Marc Beller,Jonathan S. Schildcrout,Julie R. Field,Kristin Weitzel,Rhonda M. Cooper-DeHoff,Larisa H. Cavallari,Peter H. O'Donnell,Russ B. Altman,Naveen L. Pereira,Mark J. Ratain,Dan M. Roden,Peter J. Embi,Wolfgang Sadee,Teri E. Klein,Julie A. Johnson,Mary V. Relling,Liewei Wang,Richard M. Weinshilboum,Alan R. Shuldiner,Robert R. Freimuth +29 more
TL;DR: The TPP collected and normalized pharmacogenetic implementation metrics, including gene–drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams, which may inform healthcare systems seeking to implement their own pharmacogenetics testing programs.
Journal ArticleDOI
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.
Simona Volpi,Carol J. Bult,Rex L. Chisholm,Patricia A. Deverka,Geoffrey S. Ginsburg,Howard J. Jacob,Melpomeni Kasapi,Howard L. McLeod,Dan M. Roden,Marc S. Williams,Eric D. Green,Laura Lyman Rodriguez,Samuel J. Aronson,Larisa H. Cavallari,Joshua C. Denny,Lynn G. Dressler,Julie A. Johnson,Teri E. Klein,J. Steven Leeder,Micheline Piquette-Miller,Minoli A. Perera,Laura J. Rasmussen-Torvik,Heidi L. Rehm,Marylyn D. Ritchie,Todd C. Skaar,Nikhil Wagle,Richard M. Weinshilboum,Kristin Weitzel,Robert Wildin,John Wilson,Teri A. Manolio,Mary V. Relling +31 more
TL;DR: The US landscape of research programs in PGx implementation is surveyed, current advances and clinical applications of PGx are reviewed, the obstacles that have hindered implementation are summarized, and critical knowledge gaps are identified and possible studies needed to help to address them.
Journal ArticleDOI
Multidisciplinary model to implement pharmacogenomics at the point of care.
Pedro J. Caraballo,Pedro J. Caraballo,Lucy S. Hodge,Suzette J. Bielinski,A. Keith Stewart,Gianrico Farrugia,Cloann G. Schultz,Carolyn R. Rohrer-Vitek,Janet E. Olson,Jennifer L. St. Sauver,Veronique L. Roger,Mark A. Parkulo,Iftikhar J. Kullo,Wayne T. Nicholson,Michelle A. Elliott,John L. Black,Richard M. Weinshilboum +16 more
TL;DR: A comprehensive operational model can support PGx implementation in routine prescribing and can be used as a roadmap to support similar efforts, however, there are challenges that will require major multidisciplinary and multi-institutional efforts to make PGx a universal reality.
Journal ArticleDOI
Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies
Chiara Fabbri,Katherine E. Tansey,Roy H. Perlis,Joanna Hauser,Neven Henigsberg,Wolfgang Maier,Ole Mors,Anna Placentino,Marcella Rietschel,Daniel Souery,Gerome Breen,Charles Curtis,Sang Hyuk Lee,Stephen Newhouse,Hamel Patel,Michael Conlon O'Donovan,Glyn Lewis,Gregory D. Jenkins,Richard M. Weinshilboum,Anne Farmer,Katherine J. Aitchison,Ian W. Craig,Peter McGuffin,Koen Schruers,Joanna M. Biernacka,Rudolf Uher,Cathryn M. Lewis +26 more
TL;DR: CYP2C19 polymorphisms may provide helpful information for guiding citaloprams/escitalopram treatment, despite PMs being relatively rare among Caucasians (∼2%).